跳至主要内容
临床试验/NCT06262711
NCT06262711尚未招募不适用

A Crossover Pilot Study on the Effects of Vitamin C Supplementation on Skeletal Muscle in Older Women (VICS)

University of East Anglia2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2024年2月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
16
试验地点
2
主要终点
Difference in skeletal muscle mitochondrial function between vitamin C and placebo groups.

研究概览

简要总结

As part of the ageing process muscles become weaker. One of the reasons for this is that mitochondria, the 'engines' that provide energy to fuel muscles, age and work less efficiently. Mitochondria are found in almost all cells in the human body. Mitochondria take in nutrients that are provided from food and break these down to create energy-rich compounds to fuel many different processes in the body. Muscles are loaded with mitochondria because they require a lot of energy. Mitochondria naturally produce small compounds called oxidants that can damage muscle cells and can cause inflammation. The cells in the body have a natural defence system to protect against oxidants, but when mitochondria age and become less efficient, the amount of oxidants that they produce can increase. These oxidants can damage muscles and the mitochondria themselves. Antioxidants, such as vitamin C, may help protect muscles from the damage caused by oxidants, and may help mitochondria work more efficiently. In this study, the investigators will explore whether vitamin C can help mitochondria work more efficiently, which may improve muscle strength, and help older people to remain mobile and independent for longer.

详细描述

The VICS study is a 16-week randomised, double-blind, placebo-controlled two-arm crossover pilot study conducted between the Norfolk and Norwich University Hospital (NNUH) and the Quadram Institute Clinical Research Facility (QI CRF) in Norwich, UK. Investigators are seeking women over the age of 65 years with low habitual fruit and vegetable consumption to determine whether vitamin C supplementation affects mitochondrial function, compared to a matched placebo. Participants will attend 3 clinical visits where investigators will assess skeletal muscle mitochondrial function and membrane turnover using 31-phosphorous magnetic resonance spectroscopy (31P MRS). Investigators will assess muscle strength (hand grip strength and knee extension strength) measured using handheld dynamometers, and physical function measured using the short physical performance battery (SPPB). Investigators will monitor blood levels of vitamin C and inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), and the collagen markers procollagen type-1 N-terminal propeptide (P1NP) and collagen type-1 cross-linked C telopeptide (CTX). Participants will consume one oral capsule daily (containing either 500mg vitamin C or a matched placebo) for the first 6-week intervention period, then, after a 4-week washout phase, participants will crossover and consume the other capsule daily for the second 6-week intervention period. Participants will be asked to complete a food frequency (dietary) questionnaire and physical activity questionnaire at each visit to monitor their physical activity levels and fruit and vegetable consumption.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Double blind masking

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female, aged 65 years or over
  • Non-smoker (or ex-smoker for at least 1 year).
  • Engages in less than 20 minutes of structured physical activity per week, including cycling.
  • Able to provide informed consent.
  • Able to understand basic instructions in English.
  • Willing to take daily vitamin C or placebo capsules.

排除标准

  • Consumes more than 3 fruits and vegetables per day, including fruit and vegetable juices.
  • Consumes vitamin C containing supplements, polyphenols, or other antioxidants (e.g. resveratrol or coenzyme q10).
  • Regularly takes anti-inflammatory drugs.
  • Alcohol intake >14 units/week.
  • Chronic clinical diseases (e.g., coronary artery/peripheral artery/cerebrovascular diseases, diabetes, chronic kidney disease requiring dialysis, diagnosed low renal function, neurological disorders or diseases that may affect motor/cognitive functions), except hypertension and hyperlipidaemia.
  • History of kidney stones within the preceding 12 months.
  • Contraindications for undergoing the MRI and exercise study procedures (e.g. major surgery, bilateral hip or knee replacement, non-MRI-compatible pacemaker or metal implants).
  • Parallel participation in another research project that involves an intervention.
  • Relation to, or co-habitation with, a member of the study team.
  • Those who are part of the line manager/supervisory structure of the Chief Investigator.

研究组 & 干预措施

Vitamin C, then Placebo

Experimental

Participants will first consume one 500mg vitamin C capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one placebo capsule daily for 6 weeks.

干预措施: Placebo (Dietary Supplement)

Placebo, then Vitamin C

Experimental

Participants will first consume one placebo capsule daily for 6 weeks. After a 4-week washout period, participants will crossover and consume one 500mg vitamin C capsule daily for 6 weeks.

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Difference in skeletal muscle mitochondrial function between vitamin C and placebo groups.

时间窗: Week: 6 and 16

Comparison of skeletal muscle mitochondrial oxidative capacity (estimated from 31P MRS measured phosphocreatine recovery half-time) following 6 weeks of vitamin C supplementation or 6 weeks of placebo.

次要结局

  • Difference in hand grip strength between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in knee extension strength between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in serum hs-CRP between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in plasma vitamin C between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in serum IL-6 between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in plasma P1NP between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in skeletal muscle phosphomonoester to phosphodiester ratio (PME/PDE) between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in plasma CTX between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in Short Physical Performance Battery (SPPB) score between vitamin C and placebo groups.(Week: 6 and 16.)
  • Difference in serum TNF-α between vitamin C and placebo groups.(Week: 6 and 16.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验